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Treatment of pustular psoriasis with
anakinra: a statistical analysis plan for stage
1 of an adaptive two-staged randomised
placebo-controlled trial
Suzie Cro1* , Catherine Smith2, Rosemary Wilson2 and Victoria Cornelius1
Abstract
Background: Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease. It is known to affect quality
of life at a level comparable to that from major medical and psychiatric illness, yet current treatment options are
remarkably limited. Recent evidence however suggests that interleukin-1 (IL-1) blockade with anakinra will deliver
therapeutic benefit in PPP.
Methods: Anakinra for Pustular psoriasis: Response in a Controlled Trial (APRICOT) is a two-staged, adaptive, double-
blind, randomised placebo-controlled trial which aims to test the hypothesis that IL-1 blockade with anakinra will
deliver therapeutic benefit in PPP. During stage 1 a total of 24 patients will be randomised (1:1) to receive either
placebo or anakinra. The two candidate primary outcomes are fresh pustule count (across palms and soles) and the
Palmoplantar Pustulosis Area and Severity Index (PPPASI) score, recorded at baseline and at weeks 1, 4 and 8. Analysis
at the end of stage 1 will compare treatment arms to ensure sufficient efficacy and safety in order to progress to stage
2. The primary outcome for stage 2 will also be identified following an assessment of the reliability and discriminative
ability of fresh pustule count and PPPASI. The trial is powered to detect efficacy and will recruit an additional 40
patients in stage 2 (n = 64 in total). Analysis will follow the intention-to-treat principle and analyse patients as
randomised.
Discussion: This manuscript describes the important features of the small population trial design for APRICOT and the
pre-specified statistical analysis plan for stage 1. The statistical analysis plan has been developed prior to data
extraction and in compliance with international guidelines. It will increase the transparency of the data analysis for the
APRICOT trial. The findings of the trial will help to clarify the role of anakinra in the treatment of PPP.
Trial registration: ISCRTN, ISCRTN13127147. Registered on 1 August 2016. EudraCT Number 2015-003600-23.
Registered on 1 April 2016.
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Background
Psoriasis is a chronic inflammatory skin disease with an
estimated UK prevalence of 2%. Palmoplantar pustulosis
(PPP) is a rare pustular form of the disease which affects
the hands and feet and is characterised by painful, in-
tensely inflamed, red skin studded by sheets of mono-
morphic, sterile, neutrophilic pustules [1, 2]. It is known
to affect quality of life at a level comparable to that from
major medical and psychiatric illness, yet treatment op-
tions for PPP are profoundly limited [3]. With the excep-
tion of one small, underpowered randomised controlled
trial (RCT) in PPP involving ustekinumab (n = 33) [4], no
relevant interventional trials have been performed since
2001 (highlighted in the National Institute for Health and
Care Excellence (NICE) guidelines on psoriasis) [5]. Re-
cent evidence however suggests a key pathogenic role for
interleukin-1 (IL-1), a cytokine that is known to sustain
the inflammatory responses initiated by skin keratinocytes
[6–8]. Thus, it is hypothesised that IL-1 blockade will de-
liver therapeutic benefit in PPP.
Anakinra for Pustular psoriasis: Response in a Con-
trolled Trial (APRICOT) is a two-staged, adaptive,
double-blind, randomised placebo-controlled trial which
aims to test the hypothesis that IL-1 blockade with
anakinra will deliver therapeutic benefit in PPP. As
proof-of-concept data and safety information is limited
in this rare disease (due to the small population), a
two-staged design has been adopted. An analysis at the
end of stage 1 will compare treatment arms to ensure
sufficient efficacy and safety in order to progress to the
larger stage 2 study. Since there are no validated out-
comes to measure disease change for pustular psoriasis,
the primary outcome for stage 2 will be chosen from
two candidates following an assessment of reliability and
discriminative ability at the end of stage 1. The trial is
powered to detect efficacy. Fuller details on the rationale
and proof-of-concept data are given in the study proto-
col [9]. This paper describes important features of the
innovative small population trial design and the statis-
tical principles and methods which will be applied to
analyse the data at the end of stage 1.
Methods and design
APRICOT is a small population, randomised, double-bli
nd, placebo-controlled trial of the IL-1 blockade anakinra
in PPP with two stages and an adaptive element. The in-
terim analysis for stage 1 will occur after 24 participants
have been recruited and completed 8 weeks of follow-up.
A decision to embark on stage 2, involving a further 40
participants, will be made using pre-defined STOP/GO ef-
ficacy criteria. The primary outcome for stage 2 will also
be chosen from two potential candidates (described
below) which will be assessed for reliability and discrim-
inative ability at the end of stage 1.
Primary objective
The primary objective of the APRICOT trial is to deter-
mine the efficacy of anakinra in the treatment of adults
with PPP compared to placebo. The two candidate pri-
mary outcomes are fresh pustule count over palms and
soles and the Palmoplantar Pustulosis Area and Severity
Index (PPPASI) [10]. The primary endpoint will be
change in disease activity over 8 weeks, adjusted for
baseline, measured using fresh pustule count over palms
and soles, the default primary outcome, unless the
PPPASI is assessed to be a more reliable and appropriate
measurement. The secondary objectives of APRICOT
are detailed in the trial protocol [9].
Randomisation
Participants with a diagnosis of PPP will be randomised
using blocked randomisation stratified by centre and a
1:1 ratio to receive treatment or placebo for 8 weeks.
Stage 1 will include approximately four to eight centres
(National Health Service (NHS) clinics). Participants will
be randomised using an online randomisation system by
the King’s Clinical Trials Unit to ensure allocation
concealment.
Intervention and follow-up
Every randomised participant will be required to
self-administer anakinra or matched placebo subcutane-
ous injections daily for 8 weeks. Scheduled visits for
follow-up occur at weeks 1, 4, 8, 12 and 20. The primary
endpoint is week 8. Follow-up at weeks 12 and 20 will
be used to assess disease relapse off study treatment and
adverse events.
Blinding
Participants, treating physicians, research nurses and in-
dependent outcome assessors will be unaware of treat-
ment assignment. In trials of anakinra given for other
indications, injection site reactions have been reported
to occur in 71% of patients compared to 28% in
placebo-treated patients [11]. To prevent inadvertent
unblinding, the independent outcome assessor will only
have sight of the hands and feet, not where the injection
is given. Therefore, the assessor will not be able to ob-
serve injection site reactions. To achieve this, the patient
will be invited into the clinical room by another member
of the research team and asked to remain fully dressed
apart from the feet and hands. The blinded assessor will
then be brought into the room to do the assessment and
will not be able to speak to the patient. The independent
blinded assessor may optionally wear headphones to
avoid inadvertently hearing any discussion between the
patient and clinician/other members of the research
team to maintain the blind. The analysis of stage 1 will
be conducted subgroup blind (i.e. masked as group A
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versus B) following a pre-specified analysis plan which
has been developed prior to any data extraction and is
described below. The statistician who conducts the stage
1 analysis will be unblinded on completion of stage 1
analysis. A second statistician will remain subgroup
blind throughout the trial and conduct the final analysis
subgroup blind. A detailed statistical analysis plan for
APRICOT stage 1 will be finalised once the primary out-
come for stage 2 has been confirmed.
Stage 1
Stage 1 outcomes
A total of 24 participants with PPP will be randomised
in stage 1. The stage 1 outcomes are:
1. Fresh pustule count over palms and soles: to be
included in the count, pustules must be macroscopically
visible, white/yellow in colour with no brown colour and
present on the glabrous skin of the palms and/or soles.
2. PPPASI score: a composite continuous measure
encompassing area, pustules, redness and scaling which
ranges from 0 (no PPP) to 72 (most severe PPP) [10].
Outcome assessments of fresh pustule count and
PPPASI will be carried out at each study site by an inde-
pendent assessor blind to study treatment at baseline and
at weeks 1, 4, 8 and 12. During stage 1 of the trial a second
assessor blind to treatment at each site will also use the
PPPASI to enable inter-rater reliability to be assessed.
Fresh pustule count will also be assessed by a central,
blinded assessor using photography (pre-specified views of
palms and soles at baseline (visit 1), week 1 (visit 2) and
week 8 (visit 3) of treatment). A central comparison is be-
ing made to assess whether all sites are counting consist-
ently. PPPASI is a quantitative rating score for measuring
the severity of psoriatic lesions based on area coverage,
erythema (redness), induration (thickness) and desquam-
ation (scaling). It would not be possible to assess all com-
ponents via photography. Therefore two on-site clinical
raters will take measures of PPPASI to assess the reliability
of this potential primary outcome.
The mean value of the fresh pustule count (assessed
at ‘site’) and PPPASI score across follow-up visits (aver-
aged over 1, 4 and 8 weeks for each patient), adjusted
for baseline, will be used to inform decision 1 on
Decision 1: Whether to proceed (“GO”) forward to Stage 2
Placebo group does as well as or 
better than treatment group for 
both of the two outcomes (i.e. the 
baseline adjusted mean fresh 
pustule count AND the baseline 
adjusted  mean PPPASI in the 
placebo arm averaged over, 1, 4 
and 8 weeks is the same or less 
than the treatment arm).
Treatment group does better than 
placebo group for at least one 
measure (i.e. the baseline adjusted 
mean fresh pustule count OR the 
baseline adjusted mean PPPASI in
the treatment arm averaged over, 
1, 4 and 8 weeks is less than the 
placebo arm). 
Decision 2: Choice of primary outcome for Stage 2
If ‘GO’, the choice of primary outcome for Stage 2 will by 
default be change in fresh pustule count unless PPPASI 
outcome is judged to be more reliable.  
STOP GO
Fig. 1 STOP/GO decision criteria to be employed following the completion of 8 week follow-up by n = 24 randomised patients
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efficacy (see Fig. 1). The distribution for each outcome
across follow-up visits, the agreement between the
blinded site assessments of PPPASI and the agreement
between the blinded central ‘photographic’ assessment
and blinded ‘site’ assessment of the pustule count will
be used to inform decision 2 on primary outcome selec-
tion for stage 2. The PalmoPlantar Pustulosis Investigators
Global Assessment (PPP-IGA) is used to assess eligibility
for participant inclusion in APRICOT. The PPP-IGA is a
categorical outcome measure with 5 potential levels of:
clear/almost clear/mild/moderate/severe. Participants are
required to have at least moderate disease on the
PPP-IGA. During Stage 1 of the trial a second assessor
blind to treatment at each site will also assess the
PPP-IGA to establish the reliability of this measure.
PPP-IGA will not be considered as a potential primary
outcome candidate since continuous outcomes (PPPASI
or fresh pustule count) are typically more powerful and
offer improved discrimination between treatment groups.
Stage 1 STOP/GO criteria
Pre-specified STOP/GO criteria, described in Fig. 1, estab-
lish the conditions for progression from stage 1 to stage 2
of the trial (decision 1) and selection of the primary out-
come for stage 2 (decision 2). Progression will be deter-
mined based on the ordering of the observed mean
outcome values in both treatment arms. The trial will qual-
ify for progression to stage 2 to complete the powered effi-
cacy trial provided the treatment group does better than
the placebo group for at least one of the candidate primary
outcome measures (PPPASI or fresh pustule count).
Assuming the GO criteria are achieved, the Independ-
ent Data Monitoring Committee (IDMC) will then re-
view the accumulated safety data from stage 1 and any
new drug safety data available through the drug manu-
facturer Swedish Orphan Biovitrum (SOBI) or other
sources to confirm sufficient safety. The IDMC will be
responsible for making a recommendation to the Trial
Steering Committee (TSC) and the funder, the Efficacy
and Mechanism Evaluation (EME) Programme, as to
whether the trial should continue to stage 2 and the
choice of primary outcome. To maintain blinding, the
unblinded efficacy data will only be reviewed by the
IDMC, with contributions from the unblinded statisti-
cian and funder representation (EME).
Sample size
The sample size has been calculated using a standardised
effect size, as there are two potential primary outcomes.
A large effect size of 0.9 standard deviation (SD) has
been assumed, with consideration to the cost of the drug
and requirement for daily self-administered subcutaneous
injections. Large effect sizes have also been reported with
oral retinoids [3, 12], a recommended systemic intervention
for pustular psoriasis. A sample size of 27 per arm would
be required to detect a difference of 0.9 SD with a power of
90% and a 5% significance level. We aim to recruit 32 par-
ticipants per arm (N = 64 in total) to allow for a conserva-
tive 15% withdrawal rate. RCTs involving placebo arms [3,
10] have observed a withdrawal rate of less than 5%.
The sample size for stage 1 is based on correct order-
ing of group means. Stage 1 does not involve statistical
tests. We want a high probability of continuing (‘GO’),
assuming a conservative true difference in means be-
tween the groups of 0.5 SD in favour of the treatment
group. Larger differences have been reported. With 20
patients, assuming a real difference of 0.5 SD, the prob-
ability that the baseline-adjusted means for treatment
arms will be correctly ordered (i.e. treatment > placebo) is
0.85 assuming a distribution of the difference of the two
means is normal with mean 0 and variance 2/n [13]. If
two outcomes are assessed, each with an expected differ-
ence of 0.5 SD, then the overall probability of failing to
GO is (1 – 0.85)2 = 0.0225, i.e. less than 3 in 100. There is
thus a minimal chance of failing to continue if the treat-
ment really is beneficial. Based on these rules, if there is
no treatment benefit, the probability of not progressing to
the next stage is 0.25. Whilst this is low, the balance of er-
rors has been selected to allow optimal identification of
treatment benefit and, if there is no treatment effect, can
at most be 0.5 under this design. To account for random-
isation imbalances, stage 1 will occur after 24 participants
have been randomised and followed up for at least 8 weeks.
Recruitment will be paused after the 24th participant is re-
cruited to allow for 8 weeks follow-up, analysis and review
of the data from stage 1.
General statistical principles
Stage 1 analysis will be performed after 24 participants
have been randomised and have completed 8 weeks of
follow-up. No formal statistical hypothesis testing will be
performed at this stage. Analysis will be carried out sub-
group blind and will follow the intention-to-treat (ITT)
principle. That is, all randomised patients with baseline
and at least one recorded outcome over 8 weeks will be
analysed in the treatment arms to which they were allo-
cated regardless of treatment subsequently received. No
imputation for missing data will be performed for the
stage 1 analysis. The proportion of missing data for each
outcome will be reported. Confidence intervals (CIs) will
be two-sided and at the 95% level. All data will be ana-
lysed using Stata/IC (StataCorp, College Station, TX,
USA) version 14 or above.
Statistical analysis plan
Recruitment
A Consolidated Standards of Reporting Trials (CON-
SORT) flow chart [14] will be constructed. This will
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include the number of eligible patients, number of pa-
tients agreeing to enter the trial, number of patients with-
drawing and lost to follow-up, the number continuing
through the trial and the number included in the stage 1
analysis.
Baseline comparability of randomised groups
The following baseline characteristics will be tabulated
by treatment arm: age, gender, ethnicity, smoking status,
PPPASI, fresh pustule count (palms and soles), fresh
pustule count (palms), fresh pustule count (soles), total
pustule count (palms and soles), PPP-IGA, patient global
assessment, Dermatology Life Quality Index (DLQI) and
generalised plaque psoriasis (PASI). Continuous vari-
ables will be reported as mean (SD) and median (inter-
quartile range, IQR). Categorical variables will be
presented using frequencies and proportions (as a per-
centage). These summaries will be based on observations
only, and the number of missing observations will be
reported.
Adherence to allocated treatment
The number withdrawing from the treatment schedule
will be reported by treatment arm and visit along with
reasons for withdrawal. Adherence to the 8-week, daily,
self-injection schedule is collected by responses to daily
text messages (yes or no to indicate daily dose received
or not received). Patients will also be asked for a record
of their daily injections at each visit. Self-reported adher-
ence to treatment group, collected via text and at visits,
will be reported by treatment arm and visit. The adher-
ence to the planned visit windows will be summarised
by treatment arm and visit. The use of a potent cortico-
steroid as a ‘rescue’ medication will also be reported by
treatment group.
Loss to follow-up and missing data
The number lost to follow-up will be tabulated by treat-
ment arm and visit. The proportions of participants
missing fresh pustule count and PPPASI values will be
summarised in each arm and at each time point at which
the measurement is planned.
Adverse event reporting
Adverse events (AEs) will be tabulated separately by type
(adverse event, adverse reaction, unexpected adverse re-
action, serious adverse event, serious adverse reaction or
unexpected serious adverse reaction) and by treatment
arm. AEs will be tabulated by treatment arm for both
the number of events and the number of participants
with events if participants suffer repeated events. AEs
will be recorded using terms of the local clinical investi-
gators’ choosing and will be recoded centrally using the
Medical Dictionary for Regulatory Activities (MedDRA)
for reporting at the ‘Preferred Term’ level.
Analysis for decision 1
Primary outcome assessments of fresh pustule count
(involving palms and soles) and PPPASI will be carried
out by an independent assessor blind to the study treat-
ment at each site. The mean value of each outcome
across follow-up visits (averaged over 1, 4 and 8 weeks
for each patient) and at each follow-up visit will be sum-
marised to inform decision 1 (see Fig. 1). Baseline-ad-
justed treatment group differences with 95% CIs will also
be presented and calculated using linear regression
models. An additional adjustment for centre will be made
if there are an adequate number of recruits per centre per
treatment arm (e.g. if there are > 5 recruits per centre
and/or including centre does not result in unstable model
estimates). These summaries will be based on observa-
tions only. If the baseline-adjusted mean fresh pustule
count OR the baseline-adjusted mean PPPASI in the treat-
ment arm over 1, 4 and 8 weeks is less than that in the
placebo arm, the trial will continue to stage 2. No formal
statistical testing will be conducted at this point, as the
sample size has been determined to detect the correct or-
dering of the means and not to test statistical significance.
Analysis for decision 2
We will look at how reliable fresh pustule count and
PPPASI are at the end of stage 1. The distributions of the
outcome assessments of fresh pustule count and PPPASI
will be assessed using histograms by treatment group at
each assessment point. The mean value of each outcome
will also be plotted across time by intervention arm in a
scatter plot alongside individual patient outcomes.
The standardised mean difference (SMD) will be re-
ported for each outcome and assessment point (differ-
ence of the group means divided by the pooled SD of
the group means). The SMD is unitless and can be used
to compare the discriminatory ability across the various
measures. The higher the value of the SMD, the greater
the discriminatory ability. Accompanying 95% CIs, con-
structed using the noncentral t distribution [15], will be
presented alongside the SMD.
The agreement between the ‘site’ assessors and the cen-
tral ‘photographic’ assessment will be assessed using the
method of Bland and Altman [16] allowing for the mul-
tiple observations. That is, we will visually inspect a plot
of the difference between the two assessors for each as-
sessment measuring the same quantity, i.e. for the same
patient and same time, against their mean and present
95% limits of agreement calculated as d +/− 1.96s, where
d denotes the mean difference and s denotes the standard
deviation of the differences. The limits of agreement rep-
resent the region in which 95% of differences will lie
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(assuming normality of differences). Each patient has pho-
tographs taken at baseline, week 1 and week 8. Therefore,
we will have a maximum of 72 (3 × 24) pairs of assess-
ments to compare. We will also plot differences separately
by site and assess agreement within each site where data is
sufficient. This analysis assumes the repeated differences
for each patient are independent over time, i.e. that there
is no autocorrelation. As recommended by Bland and
Altman [16], we will perform a visual check on the validity
of this assumption in a plot of the observed differences
against time, differentiated by patient. If the assumption
is violated, we will subsequently assess agreement sep-
arately by time.
A systematic difference in fresh pustule count between
the ‘site’ and ‘photographic’ assessment may be observed
due the potential for pustules that extend immediately be-
yond but are contiguous with the palms and soles to be
included in the ‘site’ assessment but not the ‘photographic’
assessment. The individual variability of the measures
(precision) will be of more importance with respect to
achieving good discrimination than the absolute agree-
ment in count. As a result, we will calculate a measure of
consistency comparing the ‘site’ and ‘photographic’ assess-
ment using the intraclass correlation coefficient (ICC).
This will be calculated using a mixed-effects analysis of
variance (ANOVA) with a random intercept for patient
and rater (‘site’ or ‘photographic’). The model will include
a fixed effect for time to allow for a different mean re-
sponse over patient and rater by time. The variability of
rater will not be included in the denominator of the ICC,
as this provides an estimate for consistency [17].
For the fresh pustule count for participant
i assessed by rater j at time k, denoted as yijk, the model
to be fitted will therefore be:
yijk ¼ β0 þ β1x1 þ β8x8 þ ci þ rij þ eijk ;
for
i = 1 to 24 patients,
j = 1 to 2 raters (1 = ‘site’, 2 = ‘photographic’),
k = 0 (baseline), 1 or 8 weeks,
xk is a dummy variable for time point k weeks (=0 or 1)
for k = 1 or 8,
β0 is a regression coefficient representing the average
outcome at baseline,
βk is a regression coefficient representing the average
difference in outcome at time point k, relative to base-
line for time k = 1, 8 weeks,
ci  N 0; σ2c
 
;
rij  N 0; σ2r
 
;
eijk  N 0; σ2e
 
:
σ2c is the variance of the measurements across subjects,
σ2r is the variance of the measurements across the two
methods for the same patient and σ2e is the unexplained
residual variance of the measurements for the same pa-
tient and method. The ICC which represents the extent
to which there is a consistent agreement among raters
will be estimated as:
ICC ¼ σ
2
c
σ2c þ σ2e
:
If the unexplained measurement variability is small in
comparison to the true differences between the patients,
the ICC will be closer to 1. This analysis assumes the re-
peated patient outcomes are independent over time, i.e.
that there is no autocorrelation. We will perform a visual
check on the validity of this assumption in a plot of out-
comes against time, differentiated by patient. If the as-
sumption is violated, we will also fit a separate model for
each time point k as:
yij ¼ β0 þ ci þ rij þ eij
and calculate and present the ICC by time. The agree-
ment between the first and second assessor PPPASI
measures, recorded at site, will be assessed using the
same methods outlined above (Bland and Altman and
ICC from mixed-effects ANOVA). The distribution for
each outcome across follow-up visits, the agreement be-
tween the two site assessor measures of PPPASI and the
agreement between the blinded central outcome assessor
and blinded site outcome assessor for pustule count will
be used to inform decision 2.
The agreement between the first and second assessor
assessments of PPP-IGA will be assessed using Cohen’s
weighted kappa statistic, κ, with a linear weighting scheme
so that the degree of disagreement between pairs of
readings is proportional to the number of grades apart.
Weighted kappa values can vary from − 1 (complete
disagreement) through 0 (chance agreement) to + 1
(complete agreement). Intermediate kappa values will be
interpreted using the criteria described by Landis and
Koch [18], where 0 < κ ≤ 0.20 = slight agreement, 0.20
< κ ≤ 0.40 = fair agreement, 0.40 < κ ≤ 0.60 =moderate
agreement, 0.60 < κ ≤ 0.80 = substantial agreement and
0.80 < κ < 1 = almost perfect agreement.
Discussion
In small populations, such as PPP, innovative trial de-
signs are necessary to ensure treatment progression is
achieved. An additional challenge in this population was
the lack of validated measures of disease activity. APRI-
COT has been designed to meet these needs.
In this article we have described the analysis for stage
1 of APRICOT, which will facilitate decision-making for
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progression to stage 2 and the most suitable as well as
reliable primary outcome measure for stage 2. This
pre-specified statistical analysis plan will increase the
transparency of the data, analysis and reporting.
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